{ }
BridgeBio Pharma Inc. has received US approval for its heart drug, Attruby, designed to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a serious heart condition. This positions the company to compete directly with Pfizer in a growing market. The drug will be priced at $18,759 for a 28-day supply.
Amazon has doubled its investment in Anthropic to $8 billion, positioning itself as a key player in the AI landscape and establishing AWS as Anthropic's primary cloud partner. This partnership will leverage Amazon's custom-designed chips for AI model training and deployment, enhancing cost-effectiveness and scalability for enterprise customers. As AI adoption accelerates, this strategic move could reshape the competitive dynamics in cloud AI services, potentially positioning Amazon for long-term success against rivals like Microsoft and Google.
The healthcare nanotechnology market is projected to grow from $308.03 billion in 2023 to $351.82 billion in 2024, with a CAGR of 14.2%, driven by rising cancer cases and advancements in nanomedicine. By 2028, the market is expected to reach $613.9 billion, fueled by innovations in theranostics and personalized medicine. North America led the market in 2023, highlighting the region's significant role in this expanding field.
The North America oncology drugs market, valued at USD 10.13 billion in 2023, is projected to grow at a CAGR of 10.38%, reaching USD 27.20 billion by 2033. Key drivers include advances in cancer research, rising cancer prevalence, and increasing demand for personalized medicine, while challenges include high drug costs and stringent regulations. The market is segmented into cytotoxic, targeted, and hormonal drugs, with targeted therapies expected to dominate due to their effectiveness and reduced toxicity.
The Global Pediatric Healthcare market is projected to grow from $175.6 billion in 2024 to $290 billion by 2032, with a CAGR of 6.5%. Key players include Abbott, Pfizer, and Merck, focusing on pharmaceuticals, nutrition, medical devices, and vaccines across various applications like hospitals and homecare. The market is expanding rapidly in the Asia-Pacific region, while North America remains the dominant market.
Private Corner has launched the PC Feeder Mérieux Innovation 2, a feeder fund focused on healthcare innovation, categorized as article 8 SFDR. This fund aims to support around 15 European companies in advanced medical technologies, with investments starting at €100,000 over 4 to 5 years. The marketing period will remain open until the end of 2025.
The US and EU have imposed significant tariffs on Chinese electric vehicle imports, raising concerns about China's overcapacity in the sector. Meanwhile, MIC2025 aims to enhance China's renewable energy and biopharmaceutical industries, with notable advancements in solar cell production and drug development, despite challenges in semiconductors and machine tools. As the end of MIC2025 approaches, China is expected to focus on high-tech goals and strengthen its position in global supply chains.
Pfizer has appointed Chris Boshoff as its new chief of research and development, effective January 1. Boshoff, who previously led the company"s cancer research and marketing, takes over from Mikael Dolsten, who stepped down after over 15 years. This leadership change comes amid pressure from activist investor Starboard and a decline in sales of Pfizer"s COVID-19 vaccine and antiviral Paxlovid, prompting a cost-cutting initiative.
Pfizer has expanded its collaboration with Flagship Pioneering by partnering with two more startups, Montai Therapeutics and Ampersand Biomedicines, to develop drug candidates for lung cancer and obesity, respectively. Under the existing alliance, Pfizer will fund R&D and has the option to license the programs. This initiative aims to help Pfizer discover up to 10 new drug candidates while providing financial support to Flagship"s startups during challenging funding conditions.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.